ZNF236

Summary

ZNF236 (zinc finger protein 236, HGNC:13028) is a protein-coding gene on chromosome 18q23, encoding Zinc finger protein 236 (Q9UL36). May be involved in transcriptional regulation. It is a selective cancer dependency (DepMap: 17.4% of cell lines).

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in cellular response to glucose stimulus. Predicted to be active in nucleus.

Source: NCBI Gene 7776 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 279 total
• Cancer dependency (DepMap): dependent in 17.4% of screened cell lines
• Transcription factor: yes — 14 downstream targets (CollecTRI)
• MANE Select transcript: NM_001306089

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13028
Approved symbol	ZNF236
Name	zinc finger protein 236
Location	18q23
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000130856
Ensembl biotype	protein_coding
OMIM	604760
Entrez	7776

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 3 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000253159, ENST00000320610, ENST00000543926, ENST00000579322, ENST00000583095, ENST00000583488, ENST00000584565, ENST00000645888, ENST00000706008

RefSeq mRNA: 2 — MANE Select: NM_001306089 NM_001306089, NM_007345

CCDS: CCDS42447, CCDS77201

Canonical transcript exons

ENST00000320610 — 31 exons

Exon	Start	End
ENSE00000894918	76851775	76851939
ENSE00000894937	76878009	76878152
ENSE00000894939	76880113	76880316
ENSE00001179496	76875492	76875664
ENSE00001179502	76871701	76871825
ENSE00001280714	76910660	76910811
ENSE00001280724	76910068	76910169
ENSE00001280732	76908320	76908573
ENSE00001280745	76904380	76904521
ENSE00001280757	76895013	76895285
ENSE00001280856	76912244	76912347
ENSE00001280886	76905155	76905415
ENSE00001280898	76899019	76899222
ENSE00001299490	76927277	76927517
ENSE00001300789	76925189	76925554
ENSE00001309083	76919776	76920058
ENSE00001325501	76923071	76923174
ENSE00001326724	76927037	76927182
ENSE00001330668	76927927	76928106
ENSE00001383033	76849526	76849668
ENSE00002702314	76822557	76822662
ENSE00002712372	76968215	76972901
ENSE00003461570	76868685	76868863
ENSE00003471855	76937156	76937343
ENSE00003521981	76959687	76959816
ENSE00003569780	76955985	76956182
ENSE00003591609	76960679	76960855
ENSE00003609826	76913747	76913898
ENSE00003626243	76881284	76881512
ENSE00003680587	76915647	76915859
ENSE00003690442	76947521	76947652

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 93.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.3388 / max 22.3062, expressed in 1209 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170803	2.3388	1209

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	93.08	gold quality
gingival epithelium	UBERON:0001949	92.83	gold quality
calcaneal tendon	UBERON:0003701	92.83	gold quality
buccal mucosa cell	CL:0002336	92.69	silver quality
germinal epithelium of ovary	UBERON:0001304	91.58	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.60	gold quality
mucosa of urinary bladder	UBERON:0001259	88.36	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.35	gold quality
corpus callosum	UBERON:0002336	87.35	gold quality
olfactory bulb	UBERON:0002264	85.20	silver quality
mucosa of paranasal sinus	UBERON:0005030	85.19	gold quality
type B pancreatic cell	CL:0000169	84.68	gold quality
gingiva	UBERON:0001828	84.25	gold quality
superficial temporal artery	UBERON:0001614	84.16	gold quality
hair follicle	UBERON:0002073	83.99	silver quality
tendon	UBERON:0000043	83.34	gold quality
epithelium of nasopharynx	UBERON:0001951	82.16	gold quality
diaphragm	UBERON:0001103	82.06	gold quality
tibia	UBERON:0000979	82.00	gold quality
visceral pleura	UBERON:0002401	81.79	gold quality
pleura	UBERON:0000977	81.18	gold quality
medial globus pallidus	UBERON:0002477	80.36	gold quality
parietal pleura	UBERON:0002400	80.25	gold quality
adrenal tissue	UBERON:0018303	79.96	gold quality
cortical plate	UBERON:0005343	79.50	gold quality
bone marrow cell	CL:0002092	79.47	gold quality
thymus	UBERON:0002370	79.17	gold quality
tonsil	UBERON:0002372	78.67	gold quality
globus pallidus	UBERON:0001875	77.90	gold quality
epithelial cell of pancreas	CL:0000083	77.80	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	5.79

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

14 targets.

Target	Regulation
ADH1B
CHMP4A
CSNK2A2
CXCL9
FERMT2
GCGR
INS
MAPK3
NEUROD1
PC
PDX1
PKLR
SLC2A2
VPS4B

miRNA regulators (miRDB)

226 targeting ZNF236, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 17.4% of screened cell lines.

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf236	ENSDARG00000095890
mus_musculus	Zfp236	ENSMUSG00000041258
rattus_norvegicus	Zfp236	ENSRNOG00000016303
drosophila_melanogaster	CG15073	FBGN0034379

Protein

Protein identifiers

Zinc finger protein 236 — Q9UL36 (reviewed: Q9UL36)

All UniProt accessions (4): Q9UL36, A0A2R8YCW3, A0A994J512, J9JID5

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous. Expression levels are highest in skeletal muscle and brain, intermediate in heart, pancreas, and placenta, and lowest in kidney, liver, and lung.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UL36-1	B	yes
Q9UL36-2	A

RefSeq proteins (2): NP_001293018, NP_031371 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR051643	Transcr_Reg_ZincFinger	Family

Pfam: PF00096, PF12874, PF13465, PF13912

UniProt features (45 total): zinc finger region 30, sequence variant 5, region of interest 3, compositionally biased region 3, splice variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UL36-F1	55.21	0.04

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 161 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GSE45365_NK_CELL_VS_BCELL_UP, LEE_NEURAL_CREST_STEM_CELL_DN, TGCACTT_MIR519C_MIR519B_MIR519A, AAGCCAT_MIR135A_MIR135B, GOBP_CELLULAR_RESPONSE_TO_CARBOHYDRATE_STIMULUS, GCAAGGA_MIR502, TATTATA_MIR374, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, BLALOCK_ALZHEIMERS_DISEASE_UP, ACATTCC_MIR1_MIR206, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, GOBP_INTRACELLULAR_GLUCOSE_HOMEOSTASIS, GOBP_CARBOHYDRATE_HOMEOSTASIS

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), cellular response to glucose stimulus (GO:0071333)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
intracellular glucose homeostasis	1
response to glucose	1
cellular response to hexose stimulus	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1075 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF236	CAPN15	O75808	480
ZNF236	CCAR2	Q8N163	477
ZNF236	MLLT3	P42568	456
ZNF236	GALR1	P47211	454
ZNF236	MED8	Q96G25	443
ZNF236	ETV7	Q9Y603	426
ZNF236	FOXP2	O15409	422
ZNF236	ZNF594	Q96JF6	417
ZNF236	CA8	P35219	416
ZNF236	TFB2M	Q9H5Q4	406
ZNF236	PTGR3	Q8N4Q0	397
ZNF236	TRDN	Q13061	379
ZNF236	PPAN	Q9NQ55	373
ZNF236	DOT1L	Q8TEK3	369
ZNF236	MAMLD1	Q13495	366

IntAct

5 interactions, top by confidence:

A	B	Type	Score
PRKAB2	ZNF236	psi-mi:“MI:0915”(physical association)	0.560
KRR1	PES1	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): ZNF236 (Affinity Capture-MS), ZNF236 (Affinity Capture-RNA), ZNF236 (Two-hybrid), ZNF236 (Affinity Capture-RNA), ZNF236 (Affinity Capture-RNA), PRKAB2 (Two-hybrid), ZNF236 (Positive Genetic), ZNF236 (Affinity Capture-MS), ZNF236 (Affinity Capture-MS), ZNF236 (Affinity Capture-RNA), ZNF236 (Affinity Capture-RNA), ZNF236 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0JPB4, A1L1J6, A4IFJ6, D3ZUU2, E9Q8T2, G5E8B9, O08954, O15060, O42409, O43623, O57415, O70237, O75626, O95625, P19382, P25932, P36197, P37275, P97469, Q20082, Q2EI20, Q3MHQ4, Q3UH06, Q4VBD9, Q5DU09, Q5R9W9, Q5SVQ8, Q5T0B9, Q5ZLR2, Q60542, Q60636, Q62947, Q64318, Q6DCW1, Q6GNP2, Q6INV8, Q6NRM0, Q7TS63, Q7ZVR6, Q80X44

Diamond homologs: A0A9P4XV22, A2ANX9, B1H2Q6, O62836, P08048, P0CJ78, P10925, P17010, P17012, P20662, P27705, P28698, P52288, P80944, Q01611, Q03081, Q03125, Q0VDT2, Q29419, Q3U3I9, Q52V16, Q567C6, Q5U2Z0, Q6B4Z5, Q7RTV3, Q95LI3, Q966L8, Q96EG3, Q9UDV6, Q9UL36, Q9Y462, B0K011, B0X9H6, E9Q6W4, O75362, O77459, P31509, P60319, P86413, Q01798

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

279 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	207
Likely benign	23
Benign	13

Top pathogenic / likely-pathogenic (0)

SpliceAI

5749 predictions. Top by Δscore:

Variant	Effect	Δscore
18:76849512:AT:A	acceptor_gain	1.0000
18:76849513:T:G	acceptor_gain	1.0000
18:76849513:T:TA	acceptor_gain	1.0000
18:76849516:A:AG	acceptor_gain	1.0000
18:76849524:A:AG	acceptor_gain	1.0000
18:76849524:AGAT:A	acceptor_gain	1.0000
18:76849525:G:GG	acceptor_gain	1.0000
18:76849525:GATG:G	acceptor_gain	1.0000
18:76849669:G:GG	donor_gain	1.0000
18:76851769:A:AG	acceptor_gain	1.0000
18:76851770:A:G	acceptor_gain	1.0000
18:76851773:A:AG	acceptor_gain	1.0000
18:76851774:G:GA	acceptor_gain	1.0000
18:76851774:GCC:G	acceptor_gain	1.0000
18:76851774:GCCAC:G	acceptor_gain	1.0000
18:76851934:G:GT	donor_gain	1.0000
18:76868682:CAGA:C	acceptor_loss	1.0000
18:76868683:A:AG	acceptor_gain	1.0000
18:76868683:A:C	acceptor_loss	1.0000
18:76868684:G:GA	acceptor_gain	1.0000
18:76868684:GA:G	acceptor_gain	1.0000
18:76868843:G:GT	donor_gain	1.0000
18:76868863:GGTA:G	donor_gain	1.0000
18:76871696:ACTAG:A	acceptor_gain	1.0000
18:76871822:ACAG:A	donor_loss	1.0000
18:76871823:CAG:C	donor_loss	1.0000
18:76871824:AG:A	donor_loss	1.0000
18:76871825:GGTAT:G	donor_loss	1.0000
18:76871826:G:GA	donor_loss	1.0000
18:76871827:T:A	donor_loss	1.0000

AlphaMissense

12232 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:76851784:T:C	C68R	1.000
18:76851793:T:C	C71R	1.000
18:76851824:T:C	L81P	1.000
18:76871759:T:C	C199R	1.000
18:76871807:C:G	H215D	1.000
18:76871809:C:A	H215Q	1.000
18:76871809:C:G	H215Q	1.000
18:76875509:T:C	C227R	1.000
18:76875518:T:C	C230R	1.000
18:76875530:T:C	F234L	1.000
18:76875531:T:C	F234S	1.000
18:76875532:T:A	F234L	1.000
18:76875532:T:G	F234L	1.000
18:76875538:G:C	Q236H	1.000
18:76875538:G:T	Q236H	1.000
18:76875549:T:C	L240P	1.000
18:76875557:C:G	H243D	1.000
18:76875559:C:A	H243Q	1.000
18:76875559:C:G	H243Q	1.000
18:76875593:T:C	C255R	1.000
18:76875594:G:A	C255Y	1.000
18:76875595:T:G	C255W	1.000
18:76875602:T:C	C258R	1.000
18:76875603:G:A	C258Y	1.000
18:76875604:T:G	C258W	1.000
18:76875614:T:C	F262L	1.000
18:76875615:T:C	F262S	1.000
18:76875616:C:A	F262L	1.000
18:76875616:C:G	F262L	1.000
18:76875633:T:C	L268P	1.000

dbSNP variants (sampled 300 via entrez): RS1000048008 (18:76862900 A>G), RS1000054036 (18:76958673 T>C), RS1000060421 (18:76936476 T>C), RS1000078624 (18:76862699 A>G), RS1000121419 (18:76949701 C>A), RS1000141812 (18:76906749 A>C), RS1000147061 (18:76891215 T>A), RS1000151766 (18:76888350 G>A,C), RS1000154712 (18:76876692 A>C), RS1000159020 (18:76869849 G>A), RS1000171031 (18:76829396 C>T), RS1000205416 (18:76844198 C>T), RS1000208101 (18:76953402 C>T), RS1000218471 (18:76931559 G>A,T), RS1000228140 (18:76823789 C>A,T)

Disease associations

OMIM: gene MIM:604760 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002007_4	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	2.000000e-06
GCST002701_38	Verbal declarative memory	2.000000e-06
GCST004863_86	Mosquito bite size	6.000000e-06
GCST009391_1470	Metabolite levels	1.000000e-06
GCST009391_1826	Metabolite levels	6.000000e-06
GCST011320_34	Type 2 diabetes or prostate cancer (pleiotropy)	2.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance
EFO:0006805	word list delayed recall measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0010407	triacylglycerol 48:4 measurement
EFO:0010411	triacylglycerol 50:4 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression, increases expression	1
butyraldehyde	decreases expression	1
cupric oxide	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Amphotericin B	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice